Get the Stockscreener App
41.56
1.54%
-0.65
After Hours:
41.61
0.05
+0.12%
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Citigroup - MarketBeat
Cytokinetics stock touches 52-week low at $41.69 amid market challenges - MSN
Cytokinetics adds pharma veteran Landry to board ahead of drug launch By Investing.com - Investing.com South Africa
Cytokinetics adds pharma veteran Landry to board ahead of drug launch - Investing.com India
Cytokinetics Appoints Robert E. Landry to Board - TipRanks
Cytokinetics Names Robert E. Landry To Board Of Directors -February 11, 2025 at 07:53 am EST - Marketscreener.com
Cytokinetics Names Robert E. Landry to Board of Directors - GlobeNewswire
Regeneron's Growth Architect Joins Cytokinetics (CYTK) Board as Company Nears Historic First Drug Launch - StockTitan
abrdn plc Acquires 102,457 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
JMP Securities maintains Cytokinetics stock with $78 target - MSN
FY2024 Earnings Forecast for Cytokinetics Issued By B. Riley - MarketBeat
Citi sets $86 price target on Cytokinetics stock with buy rating - MSN
Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 2,000 Shares of Stock - MarketBeat
Cytokinetics (NASDAQ:CYTK) Stock Price Down 8.5%What's Next? - MarketBeat
Cytokinetics (NASDAQ:CYTK) Hits New 12-Month LowShould You Sell? - MarketBeat
Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance
JMP Securities maintains Cytokinetics stock with $78 target By Investing.com - Investing.com Canada
12 Best Healthcare Stocks to Buy According to Analysts - Insider Monkey
Cytokinetics stock draws new Buy from Citi (CYTK:NASDAQ) - Seeking Alpha
Citigroup Initiates Cytokinetics at Buy With $86 Price Target -February 07, 2025 at 08:40 am EST - Marketscreener.com
Citigroup Initiates Coverage of Cytokinetics (CYTK) with Buy Recommendation - MSN
Positive Outlook for Cytokinetics Amid Rising HCM Market Demand and Developments - TipRanks
Cytokinetics’ Aficamten Poised for Market Success Amid Competitive Dynamics and Expanding HCM Opportunities - TipRanks
Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
B. Riley Adjusts Cytokinetics' Price Target to $88 From $92, Keeps Buy Rating -February 05, 2025 at 09:33 am EST - Marketscreener.com
Cytokinetics' SWOT analysis: aficamten potential drives stock outlook By Investing.com - Investing.com Canada
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics Lures Top Talent With Multi-Million Dollar Equity PackageStrategic Growth Plan Revealed - StockTitan
Cytokinetics' SWOT analysis: aficamten potential drives stock outlook - MSN
Cytokinetics’ SWOT analysis: aficamten potential drives stock outlook By Investing.com - Investing.com Nigeria
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study - MSN
Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm - The Malaysian Reserve
Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm -January 30, 2025 at 12:23 pm EST - Marketscreener.com
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics - Yahoo Finance
Cytokinetics awards $100K to heart disease advocacy groups - Investing.com
Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program - GlobeNewswire
5 Patient Groups Share $100K Prize as Cytokinetics Backs Critical Heart Disease Programs - StockTitan
Nisa Investment Advisors LLC Sells 370 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
What Are Analysts Talking About Cytokinetics (CYTK)? - Insider Monkey
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Cantor Fitzgerald Predicts Cytokinetics FY2025 Earnings - Defense World
Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $91,840.00 in Stock - MarketBeat
Cytokinetics started at buy by Stifel, aficamten highlighted - MSN
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst - Benzinga
Cytokinetics (NASDAQ:CYTK) Now Covered by Stifel Nicolaus - MarketBeat
Cantor Fitzgerald Weighs in on Cytokinetics FY2025 Earnings - MarketBeat
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Stifel starts Cytokinetics stock with Buy, $80 target By Investing.com - Investing.com Canada
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):